FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286296024> ?p ?o ?g. }

• W4286296024 endingPage "e13039" @default.
• W4286296024 startingPage "e13039" @default.
• W4286296024 abstract "e13039 Background: Palbociclib has been approved as the first CDK4/6 inhibitor in China since 2018. This study aimed to collect real-world data for retrospective analysis of the clinical outcomes and potential clinical and genetic risk factors for Palbociclib plus ET. Methods: Data of 194 HR+HER2- ABC patients who received Palbociclib plus ET between May 2018 and Dec 2020 were collected from the electronic medical record system of seven cancer centers across China. Cox regression models and bioinformatic analysis were conducted to investigate the risk factors. Results: In total, 194 patients were included in the study. Among them, 138 patients discontinued Palbociclib plus ET due to disease progression (130 patients), financial inability (5 patients), or intolerable adverse reactions (3 patients) as of the observation endpoint. With a median follow-up period of 22.4 months, the median progression-free survival (mPFS) was 12.3 months, the median time to failure (mTTF) was 11.8 months, and the median overall survival (mOS) was 35.5 months. Moreover, the 1-year PFS, TTF and OS rates were 50.8%, 49.0% and 87.6%, respectively. Of the 155 with measurable disease, the objective response rate (ORR) was 27.1%, the disease control rate (DCR) was 71.6% and the clinical benefit rate (CBR) was 81.3%. KM curves showed that first-line users had the mPFS of 19.0 months, which was significantly longer than the second-line users and the third (or higher) line users (mPFS = 10.7 and 7.2 months, p＜0.0001). Multivariate Cox regression analysis revealed several clinical features as risk factors, whereas liver metastasis was a significant risk factor for poor PFS and OS (HR = 1.993, [95%CI, 1.243-3.195], p = 0.004; HR = 2.345, [95%CI, 1.089-5.049, p = 0.029). Central nervous system (CNS) metastasis was an independent risk factor for poor OS (HR = 2.658, [95%CI, 1.152-6.136], p = 0.022). Response to CR/PR was a significant protective factor for PFS (HR = 0.289, [95%CI, 1.161-0.519], p＜0.001) but not for OS. Postmenopausal patients had a higher PFS risk than premenopausal patients (HR = 1.549, [95%CI, 1.007-2.382], p = 0.046). Seven patients received circulating tumor DNA (ctDNA) testing at the baseline and after disease progression, which showed that the mutation frequencies of FGFR1, ARID1A, ATRX, CHD4, FAT1, and PTEN increased significantly after disease progression. Conclusions: Treatment with Palbociclib plus ET exhibited favorable efficacy for HR+HER2– ABC in Chinese real-world practices, especially for non-liver, non-CNS metastasis or premenopausal patients. Early-line treatment yielded more durable benefits, and response to CR/PR indicated a better PFS prognosis. Mutations in FGFR1, ARID1A, ATRX, CHD4, FAT1, and PTEN might be associated with resistance to the combination therapy." @default.
• W4286296024 created "2022-07-21" @default.
• W4286296024 creator A5007312763 @default.
• W4286296024 creator A5014112819 @default.
• W4286296024 creator A5015595184 @default.
• W4286296024 creator A5024513841 @default.
• W4286296024 creator A5049465421 @default.
• W4286296024 creator A5050034119 @default.
• W4286296024 creator A5053985637 @default.
• W4286296024 creator A5057464475 @default.
• W4286296024 creator A5063937330 @default.
• W4286296024 creator A5065143293 @default.
• W4286296024 creator A5068453915 @default.
• W4286296024 creator A5071931643 @default.
• W4286296024 creator A5075987263 @default.
• W4286296024 creator A5078674610 @default.
• W4286296024 date "2022-06-01" @default.
• W4286296024 modified "2023-10-16" @default.
• W4286296024 title "Clinical outcomes and clinical/genetic risk factors of palbociclib plus endocrine therapy (ET) for HR+HER2− advanced breast cancer (ABC) patients in Chinese multicenter study of real-world practices." @default.
• W4286296024 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e13039" @default.
• W4286296024 hasPublicationYear "2022" @default.
• W4286296024 type Work @default.
• W4286296024 citedByCount "0" @default.
• W4286296024 crossrefType "journal-article" @default.
• W4286296024 hasAuthorship W4286296024A5007312763 @default.
• W4286296024 hasAuthorship W4286296024A5014112819 @default.
• W4286296024 hasAuthorship W4286296024A5015595184 @default.
• W4286296024 hasAuthorship W4286296024A5024513841 @default.
• W4286296024 hasAuthorship W4286296024A5049465421 @default.
• W4286296024 hasAuthorship W4286296024A5050034119 @default.
• W4286296024 hasAuthorship W4286296024A5053985637 @default.
• W4286296024 hasAuthorship W4286296024A5057464475 @default.
• W4286296024 hasAuthorship W4286296024A5063937330 @default.
• W4286296024 hasAuthorship W4286296024A5065143293 @default.
• W4286296024 hasAuthorship W4286296024A5068453915 @default.
• W4286296024 hasAuthorship W4286296024A5071931643 @default.
• W4286296024 hasAuthorship W4286296024A5075987263 @default.
• W4286296024 hasAuthorship W4286296024A5078674610 @default.
• W4286296024 hasConcept C121608353 @default.
• W4286296024 hasConcept C126322002 @default.
• W4286296024 hasConcept C143998085 @default.
• W4286296024 hasConcept C197934379 @default.
• W4286296024 hasConcept C203092338 @default.
• W4286296024 hasConcept C2775930923 @default.
• W4286296024 hasConcept C2779744173 @default.
• W4286296024 hasConcept C29456083 @default.
• W4286296024 hasConcept C530470458 @default.
• W4286296024 hasConcept C535046627 @default.
• W4286296024 hasConcept C71924100 @default.
• W4286296024 hasConceptScore W4286296024C121608353 @default.
• W4286296024 hasConceptScore W4286296024C126322002 @default.
• W4286296024 hasConceptScore W4286296024C143998085 @default.
• W4286296024 hasConceptScore W4286296024C197934379 @default.
• W4286296024 hasConceptScore W4286296024C203092338 @default.
• W4286296024 hasConceptScore W4286296024C2775930923 @default.
• W4286296024 hasConceptScore W4286296024C2779744173 @default.
• W4286296024 hasConceptScore W4286296024C29456083 @default.
• W4286296024 hasConceptScore W4286296024C530470458 @default.
• W4286296024 hasConceptScore W4286296024C535046627 @default.
• W4286296024 hasConceptScore W4286296024C71924100 @default.
• W4286296024 hasIssue "16_suppl" @default.
• W4286296024 hasLocation W42862960241 @default.
• W4286296024 hasOpenAccess W4286296024 @default.
• W4286296024 hasPrimaryLocation W42862960241 @default.
• W4286296024 hasRelatedWork W2066747782 @default.
• W4286296024 hasRelatedWork W2180467298 @default.
• W4286296024 hasRelatedWork W2294069589 @default.
• W4286296024 hasRelatedWork W2518309888 @default.
• W4286296024 hasRelatedWork W2593892593 @default.
• W4286296024 hasRelatedWork W3131900383 @default.
• W4286296024 hasRelatedWork W3132043293 @default.
• W4286296024 hasRelatedWork W3167059951 @default.
• W4286296024 hasRelatedWork W377899687 @default.
• W4286296024 hasRelatedWork W4285097448 @default.
• W4286296024 hasVolume "40" @default.
• W4286296024 isParatext "false" @default.
• W4286296024 isRetracted "false" @default.
• W4286296024 workType "article" @default.